Kidney disease drug trial halted early after only 6 patients
NCT ID NCT04652570
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called VB119 in 6 adults with primary membranous nephropathy, a kidney disease. The main goal was to check safety and how the body handles the drug, not to cure the disease. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Site
Albany, New York, 12209, United States
-
Clinical Research Site
Bethlehem, Pennsylvania, 18017, United States
-
Clinical Research Site
Dallas, Texas, 75208, United States
-
Clinical Reserach Site
Los Angeles, California, 91324, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single drug calm lupus kidney disease without a cocktail of meds?
- Immune cells may hold key to predicting kidney disease relapse
- New antibody targets hidden plasma cells to treat kidney disease
- Could a diabetes drug tame the immune system in kidney disease?
- Personalized interferon therapy aims to tame kidney disease without weakening defenses
- New gel could outperform standard therapy for kidney disease